NCM Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$750K Buy
26,699
+5
+0% +$133 0.27% 91
2025
Q4
$665K Sell
26,694
-2,616
-9% -$66K 0.25% 99
2025
Q3
$747K Sell
29,310
-1,758
-6% -$43.4K 0.29% 82
2025
Q2
$753K Buy
31,068
+7
+0% +$163 0.31% 78
2025
Q1
$787K Sell
31,061
-194
-0.6% -$5.08K 0.35% 73
2024
Q4
$829K Sell
31,255
-996
-3% -$27K 0.37% 65
2024
Q3
$933K Buy
32,251
+5
+0% +$146 0.45% 54
2024
Q2
$902K Sell
32,246
-2,277
-7% -$62.7K 0.47% 48
2024
Q1
$958K Buy
34,523
+4,314
+14% +$120K 0.54% 49
2023
Q4
$870K Sell
30,209
-1,278
-4% -$38.6K 0.53% 53
2023
Q3
$1.04M Sell
31,487
-286
-0.9% -$10.1K 0.74% 33
2023
Q2
$1.17M Buy
31,773
+43
+0.1% +$1.67K 0.81% 29
2023
Q1
$1.29M Buy
31,730
+3,141
+11% +$136K 0.97% 24
2022
Q4
$1.47M Sell
28,589
-270
-0.9% -$12.9K 0.97% 26
2022
Q3
$1.26M Sell
28,859
-166
-0.6% -$8.07K 0.96% 28
2022
Q2
$1.52M Sell
29,025
-170
-0.6% -$8.66K 1.07% 27
2022
Q1
$1.51M Sell
29,195
-401
-1% -$20.8K 0.95% 26
2021
Q4
$1.75M Buy
+29,596
New +$1.47M 1.55% 12

Other funds holding PFE

NCM Capital Management's PFE Position: Q1 2026 in Review

NCM Capital Management increased its Pfizer (PFE) stake by 0.02% in Q1 2026, buying an estimated $133 and bringing the position to 26,699 shares worth $750K. The position accounts for 0.27% of the portfolio, ranked #91.

NCM Capital Management first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.75M in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • NCM Capital Management held 26,699 shares of Pfizer worth $750K as of Q1 2026.
  • NCM Capital Management bought 5 Pfizer shares in Q1 2026, an estimated $133.
  • Pfizer made up 0.27% of NCM Capital Management's portfolio in Q1 2026, its #91 holding.
  • NCM Capital Management first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • NCM Capital Management's Pfizer position peaked at $1.75M in Q4 2021.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on NCM Capital Management's 13F filing for Q1 2026, filed 15 May 2026.